Sentiment Trading

iRadimed Corp has issued strong Q2 guidance and continues to demonstrate sustained growth, driven by robust demand for its MRI-compatible medical devices.

iRadimed Corp has reported its quarterly financial results, with its stock trading at $53.47 as of May 1, 2025, and a market capitalization of $673.14 million.